Chakma Justin

CBO Chakma Justin sells entire 166,380-share stake at $8.87 avg; stock down 55.3% from 52-week high, 43.5% in 90 days

Chakma Justin (Chief Business Officer) executed 2 separate sales totaling 166,380 shares for $1,476,147.49 on 2025-11-12, liquidating his entire position at a blended average price of $8.87. The current price of $8.21 reflects a -55.3% decline from the 52-week high of $18.35, and the stock has fallen 43.5% over the past 90 days and 25.2% in the last 30 days. At the same-ticker level, his 5 prior SPRY sales showed 4 of 5 were well-timed at the 90-day mark, establishing a pattern of selling ahead of declines at this ticker; however, this current transaction occurred after the majority of the price deterioration has already occurred, with the stock trading near 52-week lows. The company is unprofitable (net income of -$51,151,000.00 on quarterly revenue of $32,501,000.00) and trades at a P/E of 102.62, raising questions about the catalyst for this complete exit and the current risk profile of the position being liquidated.

ARS Pharma CBO Chakma sold 144,605 shares in 2 tranches (12/12–12/13) for $1.8M at avg $12.23; stock now at $11.90 (-32% from 52-week high)

Chakma Justin, Chief Business Officer of ARS Pharmaceuticals, executed 2 separate sales totaling 144,605 shares for $1,768,092.94 on 2024-12-12 and 2024-12-13, reducing his holdings by 51.5% from 280,985 to 136,380 shares. The company faces severe fundamental headwinds: Revenue of $2,068,000.00 in the latest quarter with an annual revenue decline of -97.7%, and a net income of $-19,128,000.00 over the most recent full fiscal year. The timing of this concentrated disposal coincides with a steep price trajectory: the stock is at $11.90 current price, down -32.0% from its 52-week high of $17.49 and down -15.5% over 30 days. His prior 5 trades at SPRY within the past two weeks (12/02–12/06) were also sales, establishing a continuous pattern of share reductions during a period of deteriorating market performance and sustained operational losses.

CBO Chakma Justin sells 144,640 shares (51.5% of holdings) in 3 tranches Dec 4–6 for $2,041,200.04; stock down 10.8% in 30 days.

Chakma Justin, Chief Business Officer of ARS Pharmaceuticals (SPRY), executed 3 separate sales totaling 144,640 shares for $2,041,200.04 over three trading days (December 4–6, 2024), at blended average price of $14.11. The sale represents a reduction of 51.5% of his pre-transaction holdings from 281,020 shares to 136,380 shares. The transaction occurred against a backdrop of significant company stress: the latest quarter showed revenue of $2,068,000.00 with net income of $-19,128,000.00, and annual revenue growth contracted -97.7%. The stock has declined 10.8% in the 30 days following these sales, trading currently at $14.02, approximately 19.8% below its 52-week high of $17.49.

CBo Chakma Justin sold 90,000 SPRY shares (39.8% of holdings) for $1,208,619.00 across 2024-12-02/03

Chief Business Officer Chakma Justin completed 2 separate sales totaling 90,000 shares for $1,208,619.00 on December 2–3, 2024, at prices between $13.19 and $13.67. This represents a substantial 39.8% reduction in his shareholding, from 226,380 shares to 136,380 shares post-transaction. The sales occurred while the stock traded near its 52-week range midpoint (current price $14.42 vs. 52-week high $17.49), but notably follows a pattern of four consecutive sales at SPRY over the preceding week (November 25–27, December 4), suggesting sustained near-term liquidation activity from this executive. Against a backdrop of severe fundamental stress—annual revenue declined 97.7% year-over-year, the company posted a net loss of $19,128,000.00 against quarterly revenue of $2,068,000.00, and the company remains unprofitable—the magnitude and frequency of these sales merit investor attention as a potential indicator of executive cash needs or reduced confidence in near-term prospects.

ARS Pharma CBO Chakma sells 100,000 shares (42.3% of holdings) for $1.4M across 3 days at $14.00–$14.39.

Chakma Justin, Chief Business Officer of ARS Pharmaceuticals, executed 3 separate sales totaling 100,000 shares for $1,411,742.12 across November 25–27, 2024, reducing his post-transaction holdings to 136,380 shares from 236,380 shares. The company faces significant operational headwinds: revenue of $2,068,000.00 in the latest quarter and annual revenue growth of -97.7% year-over-year, coupled with a full-year net loss of $-19,128,000.00. The blended sale price of $14.12 sits just below the current price of $14.53 but significantly below the 52-week high of $17.49. The magnitude of this sale—42.3% of pre-transaction holdings—and the company's deteriorating financial trajectory warrant investor attention to whether the CBO's conviction in the business remains intact.